Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study.
about
Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study.Profile of sarilumab and its potential in the treatment of rheumatoid arthritis.Exploring the interplay between autoimmunity and cancer to find the target therapeutic hotspots.Prognostic significance of high-mobility group box protein 1 genetic polymorphisms in rheumatoid arthritis disease outcome.Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA.Neuroendocrine and neurophysiological effects of interleukin 6 in rheumatoid arthritis.A review of sarilumab for the treatment of rheumatoid arthritis.Investigational drugs in systemic vasculitis.Resistin polymorphisms are associated with rheumatoid arthritis susceptibility in Chinese Han subjects.Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies.Sirukumab in rheumatoid arthritis refractory to sulfasalazine or methotrexate: a randomized phase 3 safety and efficacy study in Japanese patients.Efficacy of Monotherapy with Biologics and JAK Inhibitors for the Treatment of Rheumatoid Arthritis: A Systematic ReviewTreatment of Rheumatoid Arthritis with Certolizumab Pegol: Results from PROACTIVE, a Non-Interventional Study in the UK and Ireland
P2860
Q38371450-44EE338A-37D1-4245-9386-CDAE1895F0EEQ38745066-43E6DE95-D4C3-413F-8931-BCAA05636F25Q40144087-152194A1-9840-42E4-969F-0ED02B423EC9Q47108408-49644430-0A38-4DE0-926A-82641240A03EQ47131401-CE651266-1ED4-4C3D-B2EC-6D0B42DFB7F1Q47692825-F6F8FDB7-60C6-4006-A715-0C9550E55CEBQ50086851-768DBC65-149C-4B9C-BEF1-1011ABC07A48Q51834131-0ADAC926-5DB7-4CD5-8699-6AD5EF6585C5Q52645236-7EB3089E-A7A6-452E-BEAC-6EF92C51493AQ55025616-12592CDE-0AEE-447F-9F1B-105AEBB50B64Q55417294-470B4444-BE7D-4E64-951A-EAAA2939AF26Q58732393-0BC0F44B-12FE-4928-8678-746043EA773BQ58800873-C3664EB9-60EE-4DE1-922F-CC41FD9DF26B
P2860
Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study.
description
2017 nî lūn-bûn
@nan
2017 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
Efficacy and safety of sirukum ...... multinational, phase 3 study.
@ast
Efficacy and safety of sirukum ...... multinational, phase 3 study.
@en
Efficacy and safety of sirukum ...... multinational, phase 3 study.
@nl
type
label
Efficacy and safety of sirukum ...... multinational, phase 3 study.
@ast
Efficacy and safety of sirukum ...... multinational, phase 3 study.
@en
Efficacy and safety of sirukum ...... multinational, phase 3 study.
@nl
prefLabel
Efficacy and safety of sirukum ...... multinational, phase 3 study.
@ast
Efficacy and safety of sirukum ...... multinational, phase 3 study.
@en
Efficacy and safety of sirukum ...... multinational, phase 3 study.
@nl
P2093
P921
P1433
P1476
Efficacy and safety of sirukum ...... multinational, phase 3 study.
@en
P2093
Clifton O Bingham
Daniel Aletaha
Paul P Tak
Prasheen Agarwal
Regina Kurrasch
Sharon Popik
Yoshiya Tanaka
P304
P356
10.1016/S0140-6736(17)30401-4
P407
P577
2017-02-15T00:00:00Z